ClinicalTrials.gg
CompletedNCT01649856Updated Oct 11, 2017Results posted

A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma

A Phase 3 interventional study of CHOP and rituximab [MabThera/Rituxan] in Lymphoma, Large B-Cell, Diffuse, sponsored by Hoffmann-La Roche. Completed at 186 sites in 27 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-10-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
572
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 109 studies testing cyclophosphamide in Lymphoma, Large B-Cell, Diffuse — 11 open to participants now, 20 under way, 1 of them phase 3. Cyclophosphamide · Lymphoma, Large B-Cell, Diffuse.

Enrollment
4th of 99
572 · median 44
Started
2012
with 1 other
Phase 3
7 of 109
none open now
Registered
69th of 109
by date

Among the 109 studies testing cyclophosphamide in Lymphoma, Large B-Cell, Diffuse, this one is the 4th largest by enrollment of the 99 interventional ones that give a count, is one of 2 that started in 2012, is one of 7 in phase 3, and was the 69th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

11 of the 109 studies testing cyclophosphamide in Lymphoma, Large B-Cell, Diffuse are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies testing cyclophosphamide in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This multicenter, randomized, open label parallel-group study will evaluate the efficacy and safety of subcutaneous versus intravenous MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy in patients with previously untreated CD20-positive diffuse large B-Cell lymphoma. Patients will be randomized to receive either MabThera/Rituxan 1400 mg subcutaneously or MabThera/Rituxan 375 mg/m2 intravenously on Day 1 of each cycle for 8 cycles, in combination with 6-8 cycles of CHOP chemotherapy. Anticipated time on study treatment is 6 months.

03

Conditions studied

  • Lymphoma, Large B-Cell, Diffuse
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 and \</= 80 years of age at time of study inclusion
  • confirmed, previously untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) according to the WHO classification system
  • Patients with an International Prognostic Index (IPI) score 1-5, or IPI score 0 with bulky disease, defined as one lesion >/= 7.5 cm
  • At least one bi-dimensionally defined as >/= 1.5 cm in its largest dimension on CT scan, PET-CT scan or MRI
  • Adequate hematologic function
  • (EOCD) performance status \</= 2

Exclusion criteria

Exclusion Criteria:

  • Primary or secondary central nervous system lymphoma, histologic evidence of transformation to Burkitt lymphoma, primary mediastinal DLBCL, primary effusion lymphoma, primary cutaneous DLBCL, or primary DLBCL of the testis
  • Transformed lymphoma or follicular lymphoma IIIB
  • Prior therapy for DLBCL, with the exception of nodal or local irradiation
  • History of other , except for curatively treated basal or squamous cell carcinoma or melanoma of the skin, carcinoma in situ of the cervix, or a malignancy that has been treated without curative intent and has been in remission without treatment for >/= 5 years prior to enrolment
  • Inadequate renal or hepatic function
  • Known (HIV) infection or HIV seropositive status
  • Active virus (HBV) or active virus (HCV) infection. Patients with occult or prior HBV infection as defined by protocol may be included. Patients positive for HCV antibody are eligible only if polymerase chain reaction testing for HCV ribonucleic acid is negative.
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
  • to any of the individual components of CHOP, including prior receipt of anthracyclines
  • Prior treatment with cytotoxic drugs or rituximab for another condition (e.g. rheumatoid arthritis) or prior use of an anti-CD20 antibody
  • Pregnant or lactating women
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
572 participants (actual)

Study arms

  • Experimental
    A: Rituximab SC

    Drug: CHOP · Drug: rituximab [MabThera/Rituxan]

  • Active comparator
    B: Rituximab IV

    Drug: CHOP · Drug: rituximab [MabThera/Rituxan]

Interventions

  • DrugCHOP

    Drug pages: Cyclophosphamide · Doxorubicin · Vincristine · Prednisone

    CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu)

    Tumor response was assessed per criteria published by Cheson et al (1999). According to consensus recommendations, CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by greater than (\>) 75 percent (%) but still \>1.5 centimeters (cm) in size, and indeterminate bone marrow assessment. The percentage of participants with either response at the end of induction (EOI) was determined with corresponding 95% Pearson-Clopper confidence interval (CI).

    Time frame: Up to approximately 4.25 years

Secondary outcomes

  1. Cancer Treatment Satisfaction Questionnaire (CTSQ) Domain Scores

    The CTSQ is a validated 16-item questionnaire that measures three domains related to satisfaction with cancer therapy. These include expectations of therapy, feelings about side effects, and satisfaction with therapy. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.

    Time frame: At Cycle 7 (each cycle was 14 or 21 days)

  2. Rituximab Administration Satisfaction Questionnaire (RASQ) Domain Scores

    The RASQ is a 20-item questionnaire that measures five domains related to the impact of treatment administration. These include physical impact, psychological impact, impact on activities of daily living (ADLs), convenience, and satisfaction. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.

    Time frame: At Cycle 7 (each cycle was 14 or 21 days)

  3. Median Duration of Rituximab Administration for Each Treatment Cycle

    Duration of rituximab administration was defined as the time from start to end of the SC injection or IV infusion. The median duration was reported.

    Time frame: Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days)

  4. Percentage of Participants by Time Spent in the Infusion Chair/Bed for Each Treatment Cycle

    Chair time was defined as the amount of time the participant occupied an infusion chair/bed for a single treatment cycle of rituximab + CHOP chemotherapy. Where the chair time was not documented for a given cycle, it was reported as "Missing".

    Time frame: Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days)

  5. Percentage of Participants by Time Spent in the Hospital for Each Treatment Cycle

    Hospital time was defined as the amount of time the participant was in the hospital for the course of one cycle of rituximab + CHOP chemotherapy. Where the hospital time was not documented for a given cycle, it was reported as "Missing".

    Time frame: Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days)

  6. Number of Participants With an Event-Free Survival (EFS) Event

    EFS events included disease progression, relapse, initiation of other anti-lymphoma therapy, or death. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as greater than or equal to (≥) 50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.

    Time frame: Up to approximately 4.25 years

  7. Duration of EFS

    EFS was defined as the time from randomization to first occurrence of disease progression, relapse, initiation of other anti-lymphoma therapy, or death, whichever occurred first. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as a ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.

    Time frame: Up to approximately 4.25 years

  8. Number of Participants With Relapse or Death at the Time of Primary Analysis

    Tumor response was assessed according to criteria published by Cheson et al (1999). Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu. The number of participants who had experienced relapse or death prior to the clinical cut-off date (October 2014) was determined.

    Time frame: Up to approximately 2 years (assessed at Baseline, Day 1 of each cycle [maximum 8 cycles; each cycle was 14 or 21 days], every 3 months thereafter, and/or 4 weeks after early termination)

  9. Duration of Disease-Free Survival (DFS)

    DFS was defined as the time from date of initial CR/CRu to the date of relapse or death from any cause. Tumor response was assessed according to criteria published by Cheson et al (1999). Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.

    Time frame: Up to approximately 4.25 years

  10. Number of Participants With Progression, Relapse, or Death

    Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.

    Time frame: Up to approximately 4.25 years

  11. Duration of Progression-Free Survival (PFS)

    PFS was defined as the time from randomization to first occurrence of disease progression, relapse, or death from any cause. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.

    Time frame: Up to approximately 4.25 years

  12. Number of Deaths

    Time frame: Up to approximately 4.25 years

  13. Duration of Overall Survival (OS)

    OS was defined as the time from randomization to death from any cause.

    Time frame: Up to approximately 4.25 years

07

Results

Posted Feb 12, 2016

Participant flow

Participant flow — Overall Study
MilestoneRituximab Subcutaneous (SC)Rituximab Intravenous (IV)
Started369203
Completed230125
Not completed13978
Withdrew: Withdrawal by subject1414
Withdrew: Protocol violation44
Withdrew: Treatment failure11
Withdrew: Death6934
Withdrew: Stable or progressed disease53
Withdrew: Lost to follow-up2016
Withdrew: Lack of compliance61
Withdrew: Other205

Outcome measures

PrimaryPercentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu)

Tumor response was assessed per criteria published by Cheson et al (1999). According to consensus recommendations, CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by greater than (\>) 75 percent (%) but still \>1.5 centimeters (cm) in size, and indeterminate bone marrow assessment. The percentage of participants with either response at the end of induction (EOI) was determined with corresponding 95% Pearson-Clopper confidence interval (CI).

Time frame:
Up to approximately 4.25 years
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu)
percentage of participantsRituximab SCRituximab IV
Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu)50.6 (45.2 to 56.0)42.4 (35.0 to 50.0)
Statistical analysis
  • Rituximab SC vs Rituximab IV · Chi-squared · p = 0.076 · Difference in response rates: 8.2 · 95% CI -1.1 to 17.5
SecondaryCancer Treatment Satisfaction Questionnaire (CTSQ) Domain Scores

The CTSQ is a validated 16-item questionnaire that measures three domains related to satisfaction with cancer therapy. These include expectations of therapy, feelings about side effects, and satisfaction with therapy. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.

Time frame:
At Cycle 7 (each cycle was 14 or 21 days)
Reported as:
Mean · units on a scale
Cancer Treatment Satisfaction Questionnaire (CTSQ) Domain Scores
units on a scaleRituximab SCRituximab IV
Expectations of Therapy (n=280,141)79.35 ± 17.42282.94 ± 16.536
Feelings about Side Effects (n=276,141)60.69 ± 21.59457.62 ± 23.339
Satisfaction with Therapy (n=278,141)85.92 ± 11.42883.60 ± 13.451
SecondaryRituximab Administration Satisfaction Questionnaire (RASQ) Domain Scores

The RASQ is a 20-item questionnaire that measures five domains related to the impact of treatment administration. These include physical impact, psychological impact, impact on activities of daily living (ADLs), convenience, and satisfaction. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.

Time frame:
At Cycle 7 (each cycle was 14 or 21 days)
Reported as:
Mean · units on a scale
Rituximab Administration Satisfaction Questionnaire (RASQ) Domain Scores
units on a scaleRituximab SCRituximab IV
Physical Impact (n=278,140)86.24 ± 14.01281.49 ± 16.848
Psychological Impact (n=277,141)85.65 ± 13.92078.65 ± 18.233
Impact on ADLs (n=266,140)83.77 ± 16.11757.38 ± 19.230
Convenience (n=279,143)82.32 ± 13.42860.14 ± 17.473
Satisfaction (n=282,141)89.58 ± 12.05177.39 ± 18.232
SecondaryMedian Duration of Rituximab Administration for Each Treatment Cycle

Duration of rituximab administration was defined as the time from start to end of the SC injection or IV infusion. The median duration was reported.

Time frame:
Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days)
Reported as:
Median · hours
Median Duration of Rituximab Administration for Each Treatment Cycle
hoursRituximab SCRituximab IV
Cycle 1 (n=346,190)4.0 (0.10 to 11.00)4.0 (1.20 to 10.00)
Cycle 2 (n=361,178)0.1 (0.10 to 23.10)3.0 (0.50 to 10.00)
Cycle 3 (n=349,177)0.1 (0.10 to 5.50)2.8 (1.00 to 21.40)
Cycle 4 (n=346,173)0.1 (0.00 to 2.50)2.7 (0.50 to 8.00)
Cycle 5 (n=332,165)0.1 (0.00 to 2.50)2.6 (0.10 to 8.10)
Cycle 6 (n=319,162)0.1 (0.00 to 2.50)2.7 (0.10 to 20.00)
Cycle 7 (n=304,156)0.1 (0.00 to 23.60)2.7 (0.50 to 6.70)
Cycle 8 (n=305,152)0.1 (0.00 to 2.50)2.55 (0.10 to 17.90)
Overall (n=368,201)4.7 (0.10 to 28.70)19.00 (1.20 to 57.40)
SecondaryPercentage of Participants by Time Spent in the Infusion Chair/Bed for Each Treatment Cycle

Chair time was defined as the amount of time the participant occupied an infusion chair/bed for a single treatment cycle of rituximab + CHOP chemotherapy. Where the chair time was not documented for a given cycle, it was reported as "Missing".

Time frame:
Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days)
Reported as:
Number · percentage of participants
Percentage of Participants by Time Spent in the Infusion Chair/Bed for Each Treatment Cycle
percentage of participantsRituximab SCRituximab IV
Less than 30 minutes (Cycle 1)00
30 minutes to 1 hour (Cycle 1)00.5
1 to 2 hours (Cycle 1)1.40
2 to 4 hours (Cycle 1)20.617.2
4 to 12 hours (Cycle 1)69.472.4
More than 12 hours (Cycle 1)7.37.9
Missing (Cycle 1)1.42.0
Less than 30 minutes (Cycle 2)7.30
30 minutes to 1 hour (Cycle 2)2.40
1 to 2 hours (Cycle 2)17.11.1
2 to 4 hours (Cycle 2)56.136.2
4 to 12 hours (Cycle 2)12.260.1
More than 12 hours (Cycle 2)0.31.1
Missing (Cycle 2)4.61.6
Less than 30 minutes (Cycle 3)5.60
30 minutes to 1 hour (Cycle 3)2.00
1 to 2 hours (Cycle 3)22.10.5
2 to 4 hours (Cycle 3)55.938.9
4 to 12 hours (Cycle 3)12.658.4
More than 12 hours (Cycle 3)0.30.5
Missing (Cycle 3)1.71.6
Less than 30 minutes (Cycle 4)5.10
30 minutes to 1 hour (Cycle 4)2.80
1 to 2 hours (Cycle 4)21.81.1
2 to 4 hours (Cycle 4)55.036.7
4 to 12 hours (Cycle 4)13.960.6
More than 12 hours (Cycle 4)0.30.6
Missing (Cycle 4)1.11.1
Less than 30 minutes (Cycle 5)5.00.6
30 minutes to 1 hour (Cycle 5)2.40
1 to 2 hours (Cycle 5)25.21.1
2 to 4 hours (Cycle 5)53.440.2
4 to 12 hours (Cycle 5)12.856.3
More than 12 hours (Cycle 5)00.6
Missing (Cycle 5)1.21.1
Less than 30 minutes (Cycle 6)3.40.6
30 minutes to 1 hour (Cycle 6)3.10
1 to 2 hours (Cycle 6)23.01.8
2 to 4 hours (Cycle 6)56.742.5
4 to 12 hours (Cycle 6)12.353.3
More than 12 hours (Cycle 6)00
Missing (Cycle 6)1.51.8
Less than 30 minutes (Cycle 7)18.70
30 minutes to 1 hour (Cycle 7)7.00
1 to 2 hours (Cycle 7)26.94.9
2 to 4 hours (Cycle 7)40.248.8
4 to 12 hours (Cycle 7)6.044.4
More than 12 hours (Cycle 7)00
Missing (Cycle 7)1.31.9
Less than 30 minutes (Cycle 8)20.30.6
30 minutes to 1 hour (Cycle 8)6.40
1 to 2 hours (Cycle 8)29.34.4
2 to 4 hours (Cycle 8)36.750.9
4 to 12 hours (Cycle 8)5.843.4
More than 12 hours (Cycle 8)00
Missing (Cycle 8)1.60.6
SecondaryPercentage of Participants by Time Spent in the Hospital for Each Treatment Cycle

Hospital time was defined as the amount of time the participant was in the hospital for the course of one cycle of rituximab + CHOP chemotherapy. Where the hospital time was not documented for a given cycle, it was reported as "Missing".

Time frame:
Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days)
Reported as:
Number · percentage of participants
Percentage of Participants by Time Spent in the Hospital for Each Treatment Cycle
percentage of participantsRituximab SCRituximab IV
Less than 2 hours (Cycle 1)0.30
2 to 4 hours (Cycle 1)3.01.5
4 to 6 hours (Cycle 1)19.820.7
6 to 12 hours (Cycle 1)39.043.8
12 to 24 hours (Cycle 1)8.96.9
More than 24 hours (Cycle 1)26.824.1
Missing (Cycle 1)2.23.0
Less than 2 hours (Cycle 2)3.80
2 to 4 hours (Cycle 2)33.110.1
4 to 6 hours (Cycle 2)27.933.5
6 to 12 hours (Cycle 2)16.338.8
12 to 24 hours (Cycle 2)3.81.1
More than 24 hours (Cycle 2)10.311.7
Missing (Cycle 2)4.94.8
Less Than 2 hours (Cycle 3)3.60.5
2 to 4 hours (Cycle 3)37.211.9
4 to 6 hours (Cycle 3)30.230.8
6 to 12 hours (Cycle 3)14.541.6
12 to 24 hours (Cycle 3)2.82.2
More than 24 hours (Cycle 3)9.810.3
Missing (Cycle 3)2.02.7
Less Than 2 hours (Cycle 4)4.50
2 to 4 hours (Cycle 4)36.310.0
4 to 6 hours (Cycle 4)27.531.1
6 to 12 hours (Cycle 4)17.642.2
12 to 24 hours (Cycle 4)2.02.8
More than 24 hours (Cycle 4)10.210.6
Missing (Cycle 4)2.03.3
Less Than 2 hours (Cycle 5)5.00.6
2 to 4 hours (Cycle 5)39.511.5
4 to 6 hours (Cycle 5)26.434.5
6 to 12 hours (Cycle 5)16.037.4
12 to 24 hours (Cycle 5)2.11.7
More than 24 hours (Cycle 5)8.910.9
Missing (Cycle 5)2.13.4
Less Than 2 hours (Cycle 6)4.30.6
2 to 4 hours (Cycle 6)39.612.6
4 to 6 hours (Cycle 6)26.434.1
6 to 12 hours (Cycle 6)16.338.3
12 to 24 hours (Cycle 6)2.52.4
More than 24 hours (Cycle 6)8.69.0
Missing (Cycle 6)2.53.0
Less Than 2 hours (Cycle 7)17.70
2 to 4 hours (Cycle 7)40.823.5
4 to 6 hours (Cycle 7)19.936.4
6 to 12 hours (Cycle 7)10.430.9
12 to 24 hours (Cycle 7)2.82.5
More than 24 hours (Cycle 7)5.73.7
Missing (Cycle 7)2.53.1
Less Than 2 hours (Cycle 8)18.00
2 to 4 hours (Cycle 8)40.525.8
4 to 6 hours (Cycle 8)21.934.0
6 to 12 hours (Cycle 8)8.730.8
12 to 24 hours (Cycle 8)2.61.3
More than 24 hours (Cycle 8)5.85.0
Missing (Cycle 8)2.63.1
SecondaryNumber of Participants With an Event-Free Survival (EFS) Event

EFS events included disease progression, relapse, initiation of other anti-lymphoma therapy, or death. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as greater than or equal to (≥) 50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.

Time frame:
Up to approximately 4.25 years
Reported as:
Number · participants
Number of Participants With an Event-Free Survival (EFS) Event
participantsRituximab SCRituximab IV
Number of Participants With an Event-Free Survival (EFS) Event11653
SecondaryDuration of EFS

EFS was defined as the time from randomization to first occurrence of disease progression, relapse, initiation of other anti-lymphoma therapy, or death, whichever occurred first. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as a ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.

Time frame:
Up to approximately 4.25 years
Reported as:
Median · months
Duration of EFS
monthsRituximab SCRituximab IV
Duration of EFSNA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With Relapse or Death at the Time of Primary Analysis

Tumor response was assessed according to criteria published by Cheson et al (1999). Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu. The number of participants who had experienced relapse or death prior to the clinical cut-off date (October 2014) was determined.

Time frame:
Up to approximately 2 years (assessed at Baseline, Day 1 of each cycle [maximum 8 cycles; each cycle was 14 or 21 days], every 3 months thereafter, and/or 4 weeks after early termination)
Reported as:
Number · participants
Number of Participants With Relapse or Death at the Time of Primary Analysis
participantsRituximab SCRituximab IV
Number of Participants With Relapse or Death at the Time of Primary Analysis125
SecondaryDuration of Disease-Free Survival (DFS)

DFS was defined as the time from date of initial CR/CRu to the date of relapse or death from any cause. Tumor response was assessed according to criteria published by Cheson et al (1999). Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.

Time frame:
Up to approximately 4.25 years
Reported as:
Median · months
Duration of Disease-Free Survival (DFS)
monthsRituximab SCRituximab IV
Duration of Disease-Free Survival (DFS)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With Progression, Relapse, or Death

Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.

Time frame:
Up to approximately 4.25 years
Reported as:
Number · participants
Number of Participants With Progression, Relapse, or Death
participantsRituximab SCRituximab IV
Number of Participants With Progression, Relapse, or Death9538
SecondaryDuration of Progression-Free Survival (PFS)

PFS was defined as the time from randomization to first occurrence of disease progression, relapse, or death from any cause. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.

Time frame:
Up to approximately 4.25 years
Reported as:
Median · months
Duration of Progression-Free Survival (PFS)
monthsRituximab SCRituximab IV
Duration of Progression-Free Survival (PFS)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Deaths
Time frame:
Up to approximately 4.25 years
Reported as:
Number · participants
Number of Deaths
participantsRituximab SCRituximab IV
Number of Deaths5622
SecondaryDuration of Overall Survival (OS)

OS was defined as the time from randomization to death from any cause.

Time frame:
Up to approximately 4.25 years
Reported as:
Median · months
Duration of Overall Survival (OS)
monthsRituximab SCRituximab IV
Duration of Overall Survival (OS)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over Up to approximately 4.25 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab SC—155/369 (42%)319/369 (86.4%)
Rituximab IV—77/203 (37.9%)172/203 (84.7%)
Most frequent serious events
Showing 10 of 173
Most frequent serious events
EventRituximab SCRituximab IV
Febrile neutropeniaBlood and lymphatic system disorders49/36924/203
PneumoniaInfections and infestations27/3697/203
NeutropeniaBlood and lymphatic system disorders22/36910/203
PyrexiaGeneral disorders7/3693/203
LeukopeniaBlood and lymphatic system disorders1/3693/203
Septic shockInfections and infestations3/3693/203
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/3693/203
DyspnoeaRespiratory, thoracic and mediastinal disorders0/3693/203
Atrial fibrillationCardiac disorders2/3693/203
Cardiac arrestCardiac disorders1/3693/203
Most frequent other events
Showing 10 of 29
Most frequent other events
EventRituximab SCRituximab IV
NeutropeniaBlood and lymphatic system disorders104/36954/203
AnaemiaBlood and lymphatic system disorders88/36940/203
AlopeciaSkin and subcutaneous tissue disorders87/36948/203
NauseaGastrointestinal disorders79/36947/203
Neutrophil count decreasedInvestigations81/36943/203
FatigueGeneral disorders71/36929/203
ConstipationGastrointestinal disorders56/36934/203
Lymphocyte count decreasedInvestigations53/36920/203
DiarrhoeaGastrointestinal disorders52/36920/203
White blood cell count decreasedInvestigations51/36923/203

Baseline characteristics

Safety Population: All participants who received at least one dose of study drug according to treatment received.

Age, Continuous
Age, Continuous(years)Rituximab SCRituximab IVTotal
Mean60.4 ± 13.7861.0 ± 12.6360.6 ± 13.38
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab SCRituximab IVTotal
Female165100265
Male204103307
08

Study locations

186 sites
  • EHS CAC Hospital FRANTZ FANON ZABANA BLIDA; Hematology ward
    Blida, 09000, Algeria
  • Centre hospitalo-univerisitaire de Tizi Ouzou - Nedir Mohamed;Service d'hématologie
    Tizi Ouzou, 15000, Algeria
  • Cemic; Haematology
    Buenos Aires, C1431FWO, Argentina
  • Hospital Privado de Comunidad; Oncology
    Mar Del Plata, 7600, Argentina
  • Onze Lieve Vrouwziekenhuis Aalst
    Aalst, 9300, Belgium
  • ZNA Middelheim
    Antwerpen, 2020, Belgium
  • CHU Brugmann (Victor Horta)
    Bruxelles, 1020, Belgium
  • Clin Univ de Bxl Hôpital Erasme
    Bruxelles, 1070, Belgium
  • CHU Charleroi-ISPPC-Espace Santé
    Charleroi, 6000, Belgium
  • CHU de Charleroi
    Charleroi, 6000, Belgium
  • GHdC Site Notre Dame
    Charleroi, 6000, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • Jessa Zkh (Campus Virga Jesse)
    Hasselt, 3500, Belgium
  • AZ Turnhout Sint Elisabeth
    Turnhout, 2300, Belgium
  • CHR de Verviers - East Belgium
    Verviers, 4800, Belgium
  • Crio - Centro Regional Integrado de Oncologia
    Fortaleza, CE 60336-550, Brazil
  • Instituto Nacional de Cancer - INCa; Oncologia
    Rio de Janeiro, RJ 20560-120, Brazil
  • Clinicas Oncologicas Integradas - COI
    Rio De Janeiro, RJ 22290-160, Brazil
  • Hospital Giovanni Battista - Mae de Deus Center; Instituto do Cancer
    Porto Alegre, RS 90470340, Brazil
  • Hospital Amaral Carvalho
    Jau, SP 17210-080, Brazil
  • Hospital das Clinicas - FMUSP; Hematologia
    Sao Paulo, SP 05403-000, Brazil
  • University Hospital Sv.Georgi Clnic of Hematology; Hematology
    Plovdiv, 4002, Bulgaria
  • Military Medical Academy; Hematology And Oncology
    Sofia, 1431, Bulgaria
  • UMHAT Alexandrovska EAD; Hematology
    Sofia, 1431, Bulgaria
  • Lion'S Gate Hospital
    North Vancouver, British Columbia V7L 2L7, Canada
  • Cancer Care Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Regional health authority A vitalite health network
    Moncton, New Brunswick E1C 8X3, Canada
  • Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials
    Barrie, Ontario L4M 6M2, Canada
  • William Osler Health System Brampton Civic Hospital
    Brampton, Ontario L6R 3J7, Canada
  • Grand River Regional Cancer Centre
    Kitchener, Ontario N2G 1G3, Canada
  • Southlake Regional Health Center; Community Care Clinic / Oncology
    Newmarket, Ontario L3Y 2P9, Canada
  • Toronto East General Hospital; Haematology/Oncology
    Toronto, Ontario M4C 3E7, Canada
  • University Health Network; Princess Margaret Hospital; Medical Oncology Dept
    Toronto, Ontario M5G 2M9, Canada
  • Windsor Regional Cancer Centre
    Windsor, Ontario N8W 2X3, Canada
  • Clínica Imbanaco; Oncology
    Cali, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin-Antioquia, Colombia
  • Helsinki University Central Hospital; Dept of Oncology
    Helsinki, 00029, Finland
  • Middle Finland Central Hospital
    Jyväskylä, 40620, Finland
  • Oulu University Hospital; Oncology
    Oulu, 90029, Finland
  • Tampere University Hospital; Dept of Oncology
    Tampere, 33520, Finland
  • Turku Uni Central Hospital; Oncology Clinics
    Turku, 20520, Finland
  • Ch Victor Dupouy; Hematologie
    Argenteuil, 95107, France
  • Hopital Augustin Morvan; Hematologie
    Brest, 29609, France
  • Ch Du Mans; Medecine Hematologie Oncologie
    Le Mans, 72037, France
  • Centre ONCOGARD - Institut de Cancerologie du Gard
    Nimes, 30029, France
  • Ch De Saint Quentin; Medecine B10
    Saint Quentin, 02321, France
  • Hopital Sud; Hematologie Clinique
    Salouel, 80480, France
  • Hopital Yves Le Foll; Hematologie Oncologie
    St Brieuc, 22027, France
  • Clinique Ste Anne
    Strasbourg, 67000, France
  • Hopital Hautepierre; Hematologie Oncologie
    Strasbourg, 67098, France
  • Hia Sainte Anne; Medecine Interne Oncologie
    Toulon, 83041, France
  • University General Hospital of Alexandroupolis; Haemotology
    Alexandroupolis, 68100, Greece
  • General Hospital of Athens Evangelismos; Hematology
    Athens, 106 76, Greece
  • Laiko General Hospital; Hematology Clinic
    Athens, 115 27, Greece
  • Metropolitan Hospital; Hematology Dept
    Athens, 18547, Greece
  • Periph. University General Hospital of Heraklion; Hematology
    Heraklion, 711 10, Greece
  • University Hospital of Ioannina; Hematology
    Ioannina, 455 00, Greece
  • University Hospital Of Patras; Dept. Of Internal Medicine-Hematology Division
    Patras, 265 00, Greece
  • Theagenio Anticancer Hospital; Dept. of Haematology
    Thessaloniki, 54007, Greece
  • Georgios Papanikolaou Hospital; Hematology Department
    Thessaloniki, 570 10, Greece
  • Cork Uni Hospital; Oncology Dept
    Cork, Ireland
  • Mater Misericordiae Uni Hospital; Oncology
    Dublin, 7, Ireland
  • St James' Hospital; Cancer Clinical Trials Office
    Dublin, Ireland
  • Galway Uni Hospital; Oncology Dept
    Galway, Ireland
  • University Hospital Limerick - Oncology
    Limerick, Ireland
  • Haemek Medical Center; Hematology Department
    Afula, 18101, Israel
  • Rambam Medical Center; Heamatology & Bone Marrow Transplantation
    Haifa, 3109601, Israel
  • Wolfson Mc; Haematology
    Holon, 5810001, Israel
  • Shaare Zedek Medical Center; Hematology Dept.
    Jerusalem, 9103102, Israel
  • Meir Medical Center; Heamatology Dept
    Kfar Saba, 4428164, Israel
  • Beilinson Medical Center; Haematology
    Petach Tikva, 49100, Israel
  • Chaim Sheba Medical Center; Hematology BMT & CBB
    Ramat Gan, 52662, Israel
  • Kaplan Medical Center
    Rehovot, 7661041, Israel
  • Ichilov Sourasky Medical Center; Heamatology
    Tel Aviv, 6423906, Israel
  • Ospedale Civile Dello Spirito Santo; Divisione Di Ematologia
    Pescara, Abruzzo 65100, Italy
  • IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
    Meldola, Emilia-Romagna 47014, Italy
  • Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia
    Ravenna, Emilia-Romagna 48100, Italy
  • Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia
    Rimini, Emilia-Romagna 47900, Italy
  • Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica
    Aviano, Friuli-Venezia Giulia 33081, Italy
  • AOU Ospedali Riuniti; Ematologia
    Trieste, Friuli-Venezia Giulia 34125, Italy
  • Uni Cattolica; Divisione Di Ematologia
    Roma, Lazio 00168, Italy
  • Az. Osp. Sant'Andrea; U.O. C. Ematologia
    Roma, Lazio 00189, Italy
  • ASST PAPA GIOVANNI XXIII; Ematologia
    Bergamo, Lombardia 24127, Italy
  • ASST DI CREMONA; U.O.S. di Ematologia
    Cremona, Lombardia 26100, Italy
  • Ospedale Di Circolo E Fondazione Macchi; Ematologia
    Varese, Lombardia 21100, Italy
  • Ospedale Civile; S.C. Ematologia
    Pesaro, Marche 61100, Italy
  • A.O. Univ.Ospedali Riuniti Umerto I -G.M.Lancisi G.Salesi; U.O. Clinica Di Ematologia
    Torrette Di Ancona, Marche 60020, Italy
  • Ospedale Mauriziano Umberto I
    Torino, Piemonte 10128, Italy
  • Az. Osp. G. Moscati; U.O. Do Ematologia
    Taranto, Puglia 74100, Italy
  • Ospedale Oncologico A Businco-Cagliari; Ematologia Sez.
    Cagliari, Sardegna 09121, Italy
  • Azienda Ospedaliero Uni Ria Policlinico G. Martino; U.O. Di Oncologia Medica
    Messina, Sicilia 98123, Italy
  • Casa Di Cura La Maddalena; Oncoematologia E Trapianto Del Midollo Osseo
    Palermo, Sicilia 90146, Italy
  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica
    Perugia, Umbria 06156, Italy
  • Uni Degli Studi; Dip.Med.Clinica E Sperim. Ematologia
    Padova, Veneto 35128, Italy
  • Medisch Centrum Alkmaar
    Alkmaar, 1815 JD, Netherlands
  • Meander Medisch Centrum; Locatie Lichtenberg
    Amersfoort, 3818 ES, Netherlands
  • Deventer Ziekenhuis; Interne Geneeskunde
    Deventer, 7416 SE, Netherlands
  • Albert Schweitzer Ziekenhuis
    Dordrecht, 3371 NM, Netherlands
  • Maxima Medisch Centrum; Inwendige Geneeskunde
    Eindhoven, 5631 BM, Netherlands
  • Groene Hart Ziekenhuis Bleulandlocatie; Inwendige Geneeskunde
    Gouda, 2803 HH, Netherlands

Showing the first 100 of 186 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau JP, Nagler A, Rueda A, Tani M, Turgut M, Osborne S, Smith R, Pfreundschuh M. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017 Nov;102(11):1913-1922. doi: 10.3324/haematol.2017.173583. Epub 2017 Sep 21. PubMed 28935843 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2012 to primary completion in Oct 2014, 25 months.

Results were first posted in Feb 2016, 1 year 3 months after primary completion.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 25 months is below that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2012
First posted
Jul 25, 2012
StartActual
Aug 24, 2012
Primary completionActual
Oct 21, 2014
CompletionActual
Sep 16, 2016
Results first posted
Feb 12, 2016
Last update
Oct 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01649856
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 25, 2012
Start date
Aug 24, 2012
Primary completion
Oct 21, 2014
Completion
Sep 16, 2016
Results posted
Feb 12, 2016
Last update
Oct 11, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Doxorubicin · Vincristine · Prednisone · Rituximab

Start the discussion